EASY BIOInc (353810) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of EASY BIOInc KRW 17,633, price KRW 6,180, upside +185.3%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch EASY BIOInc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,737 KRW – 8,060 KRW · fair‑value band 10,532 KRW – 25,775 KRW · the 6,180 KRW price screens below the 17,633 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow EASY BIOInc in your weekly email
Every Wednesday you see whether EASY BIOInc is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EASY BIO,Inc. provides specialized piglet feed and feed additives solutions in South Korea and internationally. The company was founded in 2020 and is based in Seoul, South Korea.
Stock analysis
EASY BIOInc (353810) currently trades at 6,180 KRW, while our model-based Fair Value estimate is 17,633 KRW, implying the stock looks roughly 65.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 38,944 KRW per share, and 22 of the 24 models we run sit above the 6,180 KRW price.
Bear case: the Asset-Based group reads lowest at 2,199 KRW, and 2 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 10,532 KRW (bear) to 25,775 KRW (bull), the price of 6,180 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Consumer Non-Cyclicals sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
EASY BIOInc reported revenue of 477B KRW in FY2025 versus 129B KRW in FY2021, a compound +38.5%/yr. Reported net income was 27.8B KRW in FY2025, compounding +26.4%/yr from FY2021.
Key figures
Market cap 204B KRW (≈ $150M) · P/S ratio 1.35 · Dividend yield 3.6% · Net margin 5.8% · Return on equity 2,788% · Return on assets (EBIT) 11.7% · Operating margin 10.7% · Revenue growth (YoY) +23.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −29% fair-value upside, at 185%, 353810 screens cheaper than that median.
Fair Value models
Bear 10,532 KRWFair Value 17,633 KRWBull 25,775 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+24.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+26.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.5%
Dividend (yield on the price)3.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 9%
2025 sits 84% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +3.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Food & Tobacco · 24 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EASY BIOInc Fair Value". https://www.fairvalue-calculator.com/stock/353810
Frequently asked questions
Is EASY BIOInc (353810) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 17,633 KRW versus a price of 6,180 KRW, about +185% upside (undervalued).
What is the fair value of 353810?
Our model-based fair value for EASY BIOInc is 17,633 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 6,180 KRW.
What is the quality score of 353810?
EASY BIOInc has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EASY BIOInc (353810)?
Our model-based price target is the fair value of 17,633 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 10,532 KRW, optimistic scenario 25,775 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the EASY BIOInc stock forecast for 2026?
Our models put fair value at 17,633 KRW, about +185% upside versus a price of 6,180 KRW (undervalued). Cautious scenario 10,532 KRW, optimistic scenario 25,775 KRW. The calculation is refreshed regularly with new filings.
Does EASY BIOInc pay a dividend?
EASY BIOInc currently shows a dividend yield of about 3.62% relative to its recent price (as of Sep 24, 2026).
What growth is priced into EASY BIOInc (353810)?
For today's price to be fair in a discounted-cash-flow model, EASY BIOInc would have to grow free cash flow by +5.4 % per year for five years (discount rate 13.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +40.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 353810 use?
Our models discount EASY BIOInc at 13.6 %: a base by market capitalisation (micro), damped by beta 1.14, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EASY BIOInc that is +5.4 % per year a year over ten years, using the same discount rate (13.6 %) and the same formula as our fair value.
How much growth has EASY BIOInc (353810) delivered so far?
Over the past 5 years revenue at EASY BIOInc grew +40.2 % a year. The price currently implies +5.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EASY BIOInc (353810) growing?
The median revenue growth in the sector is +2.8 % a year. That is the yardstick for the growth priced into EASY BIOInc (+5.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EASY BIOInc (353810)?
The free-cash-flow yield on the price is 13.87 %: that much free cash flow EASY BIOInc produces per unit of market value. When it exceeds the discount rate of our models (13.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EASY BIOInc (353810)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EASY BIOInc it is 17,633 KRW per share (as of Sep 24, 2026), against a price of 6,180 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is EASY BIOInc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 353810 trades below its calculated fair value: price 6,180 KRW, fair value 17,633 KRW, a gap of about +185% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 353810?
No. The price is what the market pays today (6,180 KRW); the fair value is what the company's own numbers justify (17,633 KRW). For EASY BIOInc the two are 11,453 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is EASY BIOInc worth?
The market values EASY BIOInc at about 204B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 6,180 KRW; our models calculate a fair value of 17,633 KRW per share.
What do the bullish and bearish scenarios say about 353810?
Our models span a range for EASY BIOInc: cautious scenario 10,532 KRW, base 17,633 KRW, optimistic 25,775 KRW per share (as of Sep 24, 2026, price 6,180 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EASY BIOInc (353810)?
Balance-sheet figures for EASY BIOInc (as of Sep 24, 2026): debt of 0.63 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is 353810 from its 52-week high?
EASY BIOInc trades at 6,180 KRW, about 23% below its 52-week high of 8,060 KRW and 14% above the low of 5,412 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 17,633 KRW is for.
Which stocks are comparable to EASY BIOInc?
From the same area (Consumer Non-Cyclicals) we also value FB, URC, MONDE, CNPF, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EASY BIOInc stock attractive at the current price?
The data as of Sep 24, 2026: price 6,180 KRW, calculated fair value 17,633 KRW (+185%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 353810 calculated?
We run EASY BIOInc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 17,633 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. EASY BIOInc currently trades 185 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EASY BIOInc (353810)?
The closing price on Sep 23, 2026 was 6,180 KRW. Our model-based fair value is 17,633 KRW, about +185% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EASY BIOInc right now?
The price is below even our cautious bear case (10,532 KRW). The market is more pessimistic than our downside scenario. Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (10,532 KRW to 25,775 KRW) leaves room in how you read the outcome.
Key figures of EASY BIOInc
How large is the market capitalisation of EASY BIOInc (353810)?
The market capitalisation of EASY BIOInc is 204B KRW (≈ $150M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EASY BIOInc (353810)?
The price-to-sales ratio of EASY BIOInc is 1.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of EASY BIOInc (353810)?
The dividend yield of EASY BIOInc is 3.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EASY BIOInc (353810)?
The net margin of EASY BIOInc is 5.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EASY BIOInc (353810)?
The return on equity (ROE) of EASY BIOInc is 2,788% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EASY BIOInc (353810)?
On an EBIT basis the return on assets of EASY BIOInc is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EASY BIOInc (353810)?
The operating margin of EASY BIOInc is 10.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EASY BIOInc (353810)?
Revenue at EASY BIOInc is growing +23.5% versus a year earlier (3y avg +45.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EASY BIOInc (353810)?
Earnings per share at EASY BIOInc are growing −6.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does EASY BIOInc (353810) carry?
The net debt of EASY BIOInc is 91.4B KRW (fiscal year 2025, ≈ 3.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch EASY BIOInc in the live analysis
One click puts EASY BIOInc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
